Categories AlphaGraphs, Earnings, Health Care
MEDS Earnings: Highlights of Trxade Health’s Q2 2023 financial results
Trxade Health, Inc. (NASDAQ: MEDS), a leading health service IT company, reported a decrease in revenues for the second quarter of fiscal 2023. The company’s net loss widened from the prior-year quarter.
Revenues decreased 31% from last year to $2.25 million in the second quarter. The decline mainly reflects weak performance by the Integra subsidiary.
Net loss attributable to Trxade Health was $1.97 million or $2.90 per share in Q2, compared to a loss of $1.08 million or $1.99 per share in the same period of last year.
The TRxADE platform increased its registered users by 1,149 or 8% as of June 30, 2023, compared to June 30, 2022. For the six months ended June 30, new registrations were 291, compared to 339 a year earlier. At the end of the quarter, the company had total registered users of around 4,100+, compared to 12,962 last year.
Prior Performance
Most Popular
Nike (NKE) looks set to beat hurdles and build a brighter future
Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business
Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company
Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications
